Kissei and Maruishi ink deal on MR13A9

14 March 2017

Japanese drugmakers Kissei Pharmaceutical (TYO: 4547) and Maruishi Pharmaceutical have entered into a collaboration agreement for the development and sales/marketing of the kappa opioid receptor agonist MR13A9 for the treatment of uremic pruritus in dialysis patients. Presently, Maruishi is developing this drug in Japan.

This drug is a kappa opioid receptor agonist created by USA-based Cara Therapeutics and is the first intravenous injection formulation in the world for the treatment of uremic pruritus in dialysis patients. Maruishi in-licensed this drug from Cara Therapeutics in April 2013. Currently, Maruishi is conducting a Phase II clinical study in Japan. This drug is expected to make a great contribution to the improvement of the convenience of patients and their drug compliance.

Under this agreement, Kissei and Maruishi will collaborate for the development and sales/marketing of this drug in Japan for the above-mentioned indication. Both companies will jointly bear the expenses for the development of this drug, and after Maruishi has obtained the New Drug Approval, Kissei will sell and market this drug.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK